Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy

Hsin Tzu Liu, Heng Lin, Hann Chorng Kuo

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Objective To investigate the serum nerve growth factor (NGF) and urinary NGF levels in patients with overactive bladder syndrome (OAB) refractory to antimuscarinic therapy. Materials and Methods Thirty-four patients with OAB (17 OAB-dry and 17 OAB-wet) and 31 normal subjects were enrolled. The patients were diagnosed to have OAB based on symptoms of urgency with/without urgency incontinence and 3-day voiding diary. All OAB patients had been treated with previous antimuscarinic therapy for at least 3 months but had failed. Serum and urine were collected at baseline and after solifenacin treatment for 3 months. The serum NGF and urinary NGF levels were compared between OAB-dry and OAB-wet and between baseline and after solifenacin treatment. Results Serum NGF levels were significantly elevated in OAB (median and interquartile range, 7.367 pg/ml, 0-57.66) compared to the controls (0.0728 pg/ml, 0-0.234, P <0.001). Urinary NGF/Cr levels were significantly elevated in patients with OAB (0.685 pg/mg, 0.08-1.94) compared to the controls (0.005 pg/mg, 0-0.0275, P <0.001). Serum NGF levels were significantly correlated with urinary NGF (P = 0.002) and NGF/Cr levels (P <0.001) in OAB patients. There was no significant difference of serum NGF levels between OAB-dry and OAB-wet. The serum and urinary NGF levels remained unchanged (P = 0.504 and 0.414, respectively) in OAB patients after solifenacin therapy. The serum NGF levels were highly correlated between baseline and after solifenacin treatment (R 2 = 0.83, P <0.001). Conclusions Increased serum and urinary NGF levels in patients with OAB refractory to antimuscarinic treatment suggest these bladder disorders might be caused by chronic inflammation.

Original languageEnglish
Pages (from-to)1525-1529
Number of pages5
JournalNeurourology and Urodynamics
Volume30
Issue number8
DOIs
Publication statusPublished - Nov 2011
Externally publishedYes

Fingerprint

Overactive Urinary Bladder
Muscarinic Antagonists
Nerve Growth Factor
Serum
Therapeutics

Keywords

  • inflammation
  • nerve growth factor
  • overactive bladder
  • pathophysiology

ASJC Scopus subject areas

  • Clinical Neurology
  • Urology

Cite this

Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy. / Liu, Hsin Tzu; Lin, Heng; Kuo, Hann Chorng.

In: Neurourology and Urodynamics, Vol. 30, No. 8, 11.2011, p. 1525-1529.

Research output: Contribution to journalArticle

@article{013c499844254c9fbf27d98be8630424,
title = "Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy",
abstract = "Objective To investigate the serum nerve growth factor (NGF) and urinary NGF levels in patients with overactive bladder syndrome (OAB) refractory to antimuscarinic therapy. Materials and Methods Thirty-four patients with OAB (17 OAB-dry and 17 OAB-wet) and 31 normal subjects were enrolled. The patients were diagnosed to have OAB based on symptoms of urgency with/without urgency incontinence and 3-day voiding diary. All OAB patients had been treated with previous antimuscarinic therapy for at least 3 months but had failed. Serum and urine were collected at baseline and after solifenacin treatment for 3 months. The serum NGF and urinary NGF levels were compared between OAB-dry and OAB-wet and between baseline and after solifenacin treatment. Results Serum NGF levels were significantly elevated in OAB (median and interquartile range, 7.367 pg/ml, 0-57.66) compared to the controls (0.0728 pg/ml, 0-0.234, P <0.001). Urinary NGF/Cr levels were significantly elevated in patients with OAB (0.685 pg/mg, 0.08-1.94) compared to the controls (0.005 pg/mg, 0-0.0275, P <0.001). Serum NGF levels were significantly correlated with urinary NGF (P = 0.002) and NGF/Cr levels (P <0.001) in OAB patients. There was no significant difference of serum NGF levels between OAB-dry and OAB-wet. The serum and urinary NGF levels remained unchanged (P = 0.504 and 0.414, respectively) in OAB patients after solifenacin therapy. The serum NGF levels were highly correlated between baseline and after solifenacin treatment (R 2 = 0.83, P <0.001). Conclusions Increased serum and urinary NGF levels in patients with OAB refractory to antimuscarinic treatment suggest these bladder disorders might be caused by chronic inflammation.",
keywords = "inflammation, nerve growth factor, overactive bladder, pathophysiology",
author = "Liu, {Hsin Tzu} and Heng Lin and Kuo, {Hann Chorng}",
year = "2011",
month = "11",
doi = "10.1002/nau.21118",
language = "English",
volume = "30",
pages = "1525--1529",
journal = "Neurourology and Urodynamics",
issn = "0733-2467",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy

AU - Liu, Hsin Tzu

AU - Lin, Heng

AU - Kuo, Hann Chorng

PY - 2011/11

Y1 - 2011/11

N2 - Objective To investigate the serum nerve growth factor (NGF) and urinary NGF levels in patients with overactive bladder syndrome (OAB) refractory to antimuscarinic therapy. Materials and Methods Thirty-four patients with OAB (17 OAB-dry and 17 OAB-wet) and 31 normal subjects were enrolled. The patients were diagnosed to have OAB based on symptoms of urgency with/without urgency incontinence and 3-day voiding diary. All OAB patients had been treated with previous antimuscarinic therapy for at least 3 months but had failed. Serum and urine were collected at baseline and after solifenacin treatment for 3 months. The serum NGF and urinary NGF levels were compared between OAB-dry and OAB-wet and between baseline and after solifenacin treatment. Results Serum NGF levels were significantly elevated in OAB (median and interquartile range, 7.367 pg/ml, 0-57.66) compared to the controls (0.0728 pg/ml, 0-0.234, P <0.001). Urinary NGF/Cr levels were significantly elevated in patients with OAB (0.685 pg/mg, 0.08-1.94) compared to the controls (0.005 pg/mg, 0-0.0275, P <0.001). Serum NGF levels were significantly correlated with urinary NGF (P = 0.002) and NGF/Cr levels (P <0.001) in OAB patients. There was no significant difference of serum NGF levels between OAB-dry and OAB-wet. The serum and urinary NGF levels remained unchanged (P = 0.504 and 0.414, respectively) in OAB patients after solifenacin therapy. The serum NGF levels were highly correlated between baseline and after solifenacin treatment (R 2 = 0.83, P <0.001). Conclusions Increased serum and urinary NGF levels in patients with OAB refractory to antimuscarinic treatment suggest these bladder disorders might be caused by chronic inflammation.

AB - Objective To investigate the serum nerve growth factor (NGF) and urinary NGF levels in patients with overactive bladder syndrome (OAB) refractory to antimuscarinic therapy. Materials and Methods Thirty-four patients with OAB (17 OAB-dry and 17 OAB-wet) and 31 normal subjects were enrolled. The patients were diagnosed to have OAB based on symptoms of urgency with/without urgency incontinence and 3-day voiding diary. All OAB patients had been treated with previous antimuscarinic therapy for at least 3 months but had failed. Serum and urine were collected at baseline and after solifenacin treatment for 3 months. The serum NGF and urinary NGF levels were compared between OAB-dry and OAB-wet and between baseline and after solifenacin treatment. Results Serum NGF levels were significantly elevated in OAB (median and interquartile range, 7.367 pg/ml, 0-57.66) compared to the controls (0.0728 pg/ml, 0-0.234, P <0.001). Urinary NGF/Cr levels were significantly elevated in patients with OAB (0.685 pg/mg, 0.08-1.94) compared to the controls (0.005 pg/mg, 0-0.0275, P <0.001). Serum NGF levels were significantly correlated with urinary NGF (P = 0.002) and NGF/Cr levels (P <0.001) in OAB patients. There was no significant difference of serum NGF levels between OAB-dry and OAB-wet. The serum and urinary NGF levels remained unchanged (P = 0.504 and 0.414, respectively) in OAB patients after solifenacin therapy. The serum NGF levels were highly correlated between baseline and after solifenacin treatment (R 2 = 0.83, P <0.001). Conclusions Increased serum and urinary NGF levels in patients with OAB refractory to antimuscarinic treatment suggest these bladder disorders might be caused by chronic inflammation.

KW - inflammation

KW - nerve growth factor

KW - overactive bladder

KW - pathophysiology

UR - http://www.scopus.com/inward/record.url?scp=80054799647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054799647&partnerID=8YFLogxK

U2 - 10.1002/nau.21118

DO - 10.1002/nau.21118

M3 - Article

C2 - 21826717

AN - SCOPUS:80054799647

VL - 30

SP - 1525

EP - 1529

JO - Neurourology and Urodynamics

JF - Neurourology and Urodynamics

SN - 0733-2467

IS - 8

ER -